Synaffix
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
 Synaffix R&D facility | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2010 with capital investments from Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures |
| Founders | Prof. Dr. Floris van Delft and Dr. Sander van Berkel |
| Headquarters | , |
| Website | http://www.synaffix.com |
Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs), primarily used for cancer treatment.[1] ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are designed to target only the cancer cells and spare normal, healthy tissues.
The proprietary technology of Synaffix was developed to enable the treatment of a wide variety of cancer types and is designed to significantly enhance effectiveness while improving the safety and tolerability of these targeted cancer therapeutics.
Benchmarking studies consistently demonstrate that, with a given antibody and ADC payload, ADCs produced using Synaffix technology display significantly enhanced effectiveness and significantly enhanced tolerability and safety compared to all three major clinical-stage ADC technologies.[2][3][4] The most advanced ADC temploying Synaffix technology will given to the first cancer patients in 2018.[5]
In October 2016, Synaffix made the first public disclosure of its commercial license agreement with ADC Therapeutics Sarl (ADCT). Under the terms of the Agreement, ADCT may develop one or multiple products using Synaffix technology.[6] In October 2017, Synaffix announced that ADC Therapeutics had triggered a second target-specific license under their existing deal from 2016 to develop a second ADC product candidate using Synaffix technology. Beyond this, ADC Therapeutics retains an option to take a limited number of additional single-target licenses for their potential future programs.[7]
Most recently, Synaffix has secured granted patents covering its ADC technology that offer end-to-end protection for resulting therapeutic products through at least 2035.[4]
Synaffix was founded in 2010 based on inventions made in the field of copper-free click chemistry at the Radboud University in Nijmegen.[8] Subsequently, this chemistry was combined with the use of enzymatic antibody modification to facilitate the generation of targeted cancer therapeutics.
References[edit]
- ^ "Novel Proprietary Linkers Enable Challenging Hydrophobic Payloads Conjugation | ADC Review". ADC Review. 10 March 2015. Retrieved 2015-11-27.
- ^ van Geel, Remon (June 10, 2015). "Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates". Bioconjugate Chemistry. 26 (11): 2233–42. doi:10.1021/acs.bioconjchem.5b00224. PMID 26061183.
- ^ "Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board | Synaffix". 2016-07-20. Retrieved 2016-07-28.
- ^ a b "2017 - Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States |" (Press release). 16 May 2017.
- ^ "2017 - Synaffix website |".
- ^ "2016 - Synaffix Enters into a Commercial License Agreement with ADC Therapeutics |".
- ^ "2017 - ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement |" (Press release). 11 October 2017.
- ^ "2014 - SynAffix raises Series A investment round to advance its GlycoConnectTM technology for creating next-generation ADCs | BioGeneration Ventures B.V." www.biogenerationventures.com. Retrieved 2015-11-27.